Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD

• Cingulate Inc (NASDAQ: CING) is preparing to initiate a Phase 3 adult dose-optimization study later this year for its lead candidate, CTx-1301, to assess the onset and duration of efficacy and safety in adults with Attention Deficit / Hyperactivity Disorder (ADHD).

• The study is expected to commence in December 2022.

• The company executed a Master Services Agreement with Societal CDMO Inc (NASDAQ: SCTL) to manufacture all clinical, registration, and commercial batches of Cingulate's lead candidate CTx-1301, an investigational medication for ADHD.

• In addition, the CTx-1301 Phase 3 fixed-dose pediatric and adolescent safety and efficacy study is now expected to commence in mid-2023 after the final two dosage strengths for this study are completed by Societal CDMO.

• Earlier this year, Cingulate expected to start the fixed-dose study in Q2 of 2022.

• Assuming positive clinical results from Phase 3 trials and the food effect study with data expected in December 2022, the company plans to submit a marketing application to the FDA in 1H of 2024 under the Section 505(b)(2) pathway.

• Price Action: CING shares closed 14.3% lower at $0.90 during after-hours trading on Monday.

See more from Benzinga

• GE Posts Smaller Than Expected Q3 Earnings, Plans Restructuring In Vernova Unit

• Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.